SEC's Aveo probe puts MD Anderson chief DePinho in spotlight; Curis gains conditional EU OK on Erivedge;

 @FierceBiotech: ICYMI last week: The biotech IPO scene turns red hot. Special report | Follow @FierceBiotech

 @JohnCFierce:  Vivus pushes back shareholder meeting, a sure sign they are losing the fight with FMC. Report | Follow @JohnCFierce

 @RyanMFierce: Europe eyes social media and mobile for data on bad drug reactions. Story | Follow @RyanMFierce

 @EmilyMFierce: You can't patent human genes. So why are genetic testing companies getting sued? Article | Follow @EmilyMFierce

> The SEC probe into Aveo Pharmaceuticals' ($AVEO) controversial actions around tivozanib has put co-founder and UT MD Anderson Cancer Center Ronald DePinho in the spotlight. In particular, DePinho's comments on CNBC about Aveo last year as the FDA was raising objections to the tivo study have spurred questions about what he knew, and when. He put out a statement in May saying: "Discussing Aveo was not the purpose for the interview, and I was not anticipating any questions relating to Aveo. Regardless, commenting on the company was a poor decision on my part, and I apologized for it shortly thereafter." Story

> Curis ($CRIS) says that the EU has provided conditional approval of Erivedge (tismodegib) for basal cell carcinoma, a rare form of skin cancer. Release

> ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics, and BZL Biologics announced an exclusive licensing and collaboration agreement for an antibody against PSMA-positive prostate cancers. Release

Medical Device News

 @FierceMedDev: AngioDynamics' FY 2013 reflects a partial upswing. Story | Follow @FierceMedDev

 @MarkHFierce: Give us your FMD Fierce 15 nominations today - Device and Dx nominations welcome. Submit here | Follow @MarkHFierce

 @DamianFierce: AstraZeneca signs up with genomics outfit Blackfield for cancer R&D. More | Follow @DamianFierce

> J&J smacked with Canadian lawsuit claiming vaginal mesh implant damage. News

> Given Imaging's PillCam Colon capsule wins Japanese approval. Report

> FDA hits Medtronic with Class I recall over faulty insulin pump part. Story

Pharma News

 @FiercePharma: AstraZeneca CFO jumps ship in latest executive switcheroo. News | Follow @FiercePharma

 @EricPFierce:  Novartis CEO Jimenez says China is a difficult market, but worth it. I wonder if #GSK agrees right now. Article | Follow @EricPFierce

 @CarlyHFierce: Here's Vivus' release re: delaying its shareholder meeting - says First Manhattan made false statements. Release | Follow @CarlyHFierce

> Roche may want Alexion, but is the price right? Story

> China calls GSK 'godfather' in alleged bribery scheme. News

CRO News

> Corgenix signs CMO deal with EDP Biotech. Item

> Theorem, Emergo team up for devices and diagnostics. News

> NIH, industry back out of India as trials slow to standstill. Article

> Catalent inks Biota flu deal, shifts delivery biz. Story

Biotech IT News

> Europe eyes social media and mobile for data on bad drug reactions. News

> High-profile VC Sequoia backs clinical tech startup Comprehend in $8.4M round. Story

> Boehringer Ingelheim expands use of Big Data tech for pharma research. Article

> ChemAxon extends pharma software streak with Schrödinger deal. Item

And Finally... Saudi officials have called on the young, old and unwell to avoid the pilgrimage to Mecca this year, worried that the mass arrival of hundreds of thousands of pilgrims could trigger the rapid spread of the deadly MERS coronavirus. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.

The RNAi therapy drove a 72% reduction in urinary oxalate from baseline, boosting Alnylam’s hopes of using the drug in a broad patient population.